To broaden its capabilities for research, The Institute for Therapeutic Discovery is renewing its capital-raising efforts. Founded by John McMichael, Ph.D., the Institute is a not-for-profit organization specializing in discovery and early-stage development of therapeutic agents for chronic diseases. The principal features of these agents are that they are derived from naturally-occurring molecules, and that they are administered in low doses. This profile offers a substantial cost savings in terms of research, development, manufacturing, and time. In addition, to date these agents have produced very few, and only minor, adverse side-effects.
